^
    4d
    A Case of Angioimmunoblastic T-Cell Lymphoma Misdiagnosed as Eczema-Like Dermatitis in an Elderly Patient. (PubMed, Clin Cosmet Investig Dermatol)
    This case underscores the diagnostic complexity of AITL presenting with predominant allergic-like skin lesions and highlights the importance of considering underlying lymphoproliferative disorders in elderly patients with persistent, recurrent, or atypical dermatoses. Timely histopathological and immunophenotypic evaluation is essential for accurate diagnosis and appropriate management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MME (Membrane Metalloendopeptidase)
    4d
    Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    |
    azacitidine • decitabine • Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    4d
    CFT7455-1101: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma (clinicaltrials.gov)
    P1, N=224, Active, not recruiting, C4 Therapeutics, Inc. | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • cemsidomide (CFT7455)
    5d
    Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework. (PubMed, Biomed Chromatogr)
    Belinostat and its potential metabolites have often been qualitatively and quantitatively estimated and tracked using several analytical methods including UPLC-MS/MS, HPLC-UV, FTIR, TLC, NMR, and ESI-MS. In terms of therapeutic use of belinostat, this review demonstrates how important it is to understand the metabolism and degradation pathways of belinostat, as well as possible drug-drug interactions.
    Review • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Beleodaq (belinostat)
    5d
    A challenging case of facial oedemas revealing a systemic peripheral T-cell lymphoma, not otherwise specified. (PubMed, Eur J Dermatol)
    In our case, as extracutaneous disease was present from the beginning, the diagnosis would be better classified as systemic (non-primary cutaneous) PTCL-NOS. This report emphasizes the importance of repeated biopsies and expert reviews for diagnosing and managing PTCL, which can have a highly variable and poor prognosis.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD5 (CD5 Molecule) • GZMB (Granzyme B) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • PRF1 (Perforin 1)
    5d
    Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Fudan University | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial primary completion date
    |
    zeprumetostat (SHR-2554) • AiSuDa (ivarmacitinib)
    8d
    Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • Orencia (abatacept)
    9d
    ASTX660-01: Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1/2, N=253, Active, not recruiting, Taiho Oncology, Inc. | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date
    |
    tolinapant (ASTX660)
    12d
    Analysis of Immunophenotype and Clinical Biological Characteristics of Mature T-Cell Lymphoma and Clonal T Cells of Undetermined Significance (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    TRBC1 can be used as an ideal indicator for rapid detection of T cell clonality, Multi-parameter flow cytometry (MFC) combined with TCR gene rearrangement testing has good clinical value in distinguishing T-cell lymphoma from T-cell clonal proliferation of uncertain significance.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    12d
    Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26). (PubMed, Blood Cancer J)
    No TRAEs leading to fatal outcomes were reported. This study suggests the potential of golidocitinib as maintenance therapy for patients with PTCL.
    P2 data • Journal
    |
    JAK1 (Janus Kinase 1)
    |
    golidocitinib (DZD4205)
    12d
    Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=45, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Sep 2028 --> Apr 2029 | Initiation date: Sep 2025 --> Apr 2026 | Trial primary completion date: Sep 2027 --> Jan 2029
    Trial completion date • Trial initiation date • Trial primary completion date